RU2002130448A - PHARMACEUTICAL COMPOSITION HAVING A THROMBOLYTIC AND FIBRINOLYTIC ACTION - Google Patents

PHARMACEUTICAL COMPOSITION HAVING A THROMBOLYTIC AND FIBRINOLYTIC ACTION

Info

Publication number
RU2002130448A
RU2002130448A RU2002130448/15A RU2002130448A RU2002130448A RU 2002130448 A RU2002130448 A RU 2002130448A RU 2002130448/15 A RU2002130448/15 A RU 2002130448/15A RU 2002130448 A RU2002130448 A RU 2002130448A RU 2002130448 A RU2002130448 A RU 2002130448A
Authority
RU
Russia
Prior art keywords
composition according
thrombolytic
maput22
dextran
pharmaceutical composition
Prior art date
Application number
RU2002130448/15A
Other languages
Russian (ru)
Other versions
RU2216348C1 (en
Inventor
Анатолий Александрович Белогуров
Роберт Шалвович Бибилашвили
Ярослав Георгиевич Гурский
Евгений Петрович Дельвер
Ирина Ивановна Товарова
Original Assignee
Общество с ограниченной ответственностью "Научно-производственное предприятие "Техноген"
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Научно-производственное предприятие "Техноген" filed Critical Общество с ограниченной ответственностью "Научно-производственное предприятие "Техноген"
Priority to RU2002130448/14A priority Critical patent/RU2216348C1/en
Priority claimed from RU2002130448/14A external-priority patent/RU2216348C1/en
Application granted granted Critical
Publication of RU2216348C1 publication Critical patent/RU2216348C1/en
Publication of RU2002130448A publication Critical patent/RU2002130448A/en

Links

Claims (5)

1. Фармацевтическая композиция, обладающая тромболитическим и фибринолитическим действием, содержащая в качестве действующего вещества модифицированный активатор плазминогена урокиназного типа мАПУТ22 с удельной активностью 80000-100000 МЕ/мг фермента, имеющий аминокислотную последовательность SEQ ID №1, в эффективной терапевтической дозе и инертный наполнитель.1. A pharmaceutical composition having thrombolytic and fibrinolytic action, containing as active substance a modified urokinase plasminogen activator type MAPUT22 with a specific activity of 80,000-100,000 IU / mg of the enzyme, having the amino acid sequence of SEQ ID No. 1, in an effective therapeutic dose and an inert excipient. 2. Композиция по п.1, содержащая в качестве инертного наполнителя натрия хлорид и декстран с молекулярной массой 10000-70000.2. The composition according to claim 1, containing as an inert filler sodium chloride and dextran with a molecular weight of 10000-70000. 3. Композиция по пп.1 и 2, содержащая компоненты в следующем соотношении, мас.%:3. The composition according to claims 1 and 2, containing components in the following ratio, wt.%: МАПУТ22 6,2-9,1MAPUT22 6.2-9.1 Натрия хлорид 49,5-73,9Sodium Chloride 49.5-73.9 Декстран 26,1-39,1Dextran 26.1-39.1 4. Композиция по п.3, содержащая в качестве декстрана реополиглюкин с молекулярной массой 30000-40000.4. The composition according to claim 3, containing as dextran reopoliglyukin with a molecular weight of 30000-40000. 5. Композиция по пп.1, 2 и 4, содержащая компоненты в следующем соотношении, мас.%:5. The composition according to claims 1, 2 and 4, containing components in the following ratio, wt.%: МАПУТ22 6,8-8,3MAPUT22 6.8-8.3 Натрия хлорид 54,5-66,6Sodium chloride 54.5-66.6 Реополиглюкин 28,8-35,2Reopoliglyukin 28.8-35.2
RU2002130448/14A 2002-11-14 2002-11-14 Pharmaceutical composition eliciting thrombolytic and fibrinolytic effect RU2216348C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2002130448/14A RU2216348C1 (en) 2002-11-14 2002-11-14 Pharmaceutical composition eliciting thrombolytic and fibrinolytic effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2002130448/14A RU2216348C1 (en) 2002-11-14 2002-11-14 Pharmaceutical composition eliciting thrombolytic and fibrinolytic effect

Publications (2)

Publication Number Publication Date
RU2216348C1 RU2216348C1 (en) 2003-11-20
RU2002130448A true RU2002130448A (en) 2004-06-10

Family

ID=32028282

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002130448/14A RU2216348C1 (en) 2002-11-14 2002-11-14 Pharmaceutical composition eliciting thrombolytic and fibrinolytic effect

Country Status (1)

Country Link
RU (1) RU2216348C1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335167B1 (en) * 2007-02-26 2011-01-24 Proyecto De Biomedicina Cima, S.L. USE OF METALOPROTEINASE MATRIX-10 (MMP10) FOR THROMBOLITIC TREATMENTS.
RU2448156C1 (en) * 2011-03-17 2012-04-20 Эспосито Трейдинг Лтд Method of producing lyophilised substance
RU2765043C1 (en) * 2020-12-02 2022-01-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Two-component pharmaceutical composition having fibrinolytic effect

Similar Documents

Publication Publication Date Title
EP1232251B1 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
Lijnen et al. Fibrinolytic agents: mechanisms of activity and pharmacology
US6964764B2 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
HU185223B (en) Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen
EP0217379A2 (en) Thrombolytic composition and a process for production thereof
CN1122573A (en) Oxygen-reduced aqueous solution of factor VIII
US4980165A (en) Pharmaceutical formulations of plasminogen activator proteins
JPH0680015B2 (en) Pharmaceutical composition
KR890000103A (en) Method for preparing high concentration solution of protein with tissue plasminogen activator (t-PA) activity, solution containing protein with t-PA activity, and use of solution in human and veterinary medicine
AU623347B2 (en) Thrombolytic agent
US6969515B2 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
EP1459738B1 (en) Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties
RU2002130448A (en) PHARMACEUTICAL COMPOSITION HAVING A THROMBOLYTIC AND FIBRINOLYTIC ACTION
Lijnen et al. Mechanisms of plasminogen activation by mammalian plasminogen activators
HU216793B (en) Process for producing pharmaceutical compositions containing nonglycozylized k2p pro t-pa
US6759042B2 (en) Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
Goldfarb et al. Degradation of glycoprotein and collagenous components of the basement membrane: studies with urokinase-type plasminogen activator, α-thrombin, and plasmin
Sawa et al. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-α converting enzyme (TACE)
PT98823A (en) METHOD FOR PREPARING A HYBRID PLASMINOGEN ACTIVATOR
JPS61236730A (en) Medicine containing plasminogen activator
WO2001080811A2 (en) Mmp-2 propeptide for use as antiangiogenic or antitumor agent
Thomson New thrombolytic drugs
JP2005532377A (en) A novel combination formulation based on magnesium salt and fibrinolytic agent
DK163175B (en) SYNERGISTIC PHARMACEUTICAL COMBINATION PREPARATION OF PLASMINOGEN ACTIVATOR, T-PA, AND OXYPURINOL